Danis Judit, Széll Márta
Department of Immunology, Albert Szent-Györgyi Medical School, University of Szeged, H-6720 Szeged, Hungary.
HUN-REN-SZTE Dermatological Research Group, University of Szeged, H-6720 Szeged, Hungary.
Noncoding RNA. 2025 Sep 19;11(5):69. doi: 10.3390/ncrna11050069.
Psoriasis is a chronic inflammatory skin disorder affecting approximately 2% of the global population, characterized by abnormal keratinocyte proliferation and dysregulated immune responses. This review examines the emerging role of long non-coding RNAs (lncRNAs) in psoriasis pathogenesis, highlighting their significance as regulatory molecules in disease initiation, progression, and chronicity. LncRNAs demonstrate distinct expression patterns in psoriatic lesions, with upregulated transcripts such as MALAT1, XIST, MIR31HG, and HOTAIR promoting keratinocyte hyperproliferation, inhibiting apoptosis, and amplifying inflammatory cascades through mechanisms including microRNA sponging and transcription factor modulation. These molecules primarily target key signaling pathways including NF-κB, STAT3, and PI3K/AKT. Conversely, downregulated lncRNAs like NEAT1, MEG3, and PRINS normally function as tumor suppressor molecules that maintain epidermal homeostasis through pro-apoptotic and anti-inflammatory mechanisms. Their reduced expression contributes to the pathological hyperproliferative phenotype characteristic of psoriatic skin. Importantly, genetic variants within lncRNA loci have been identified as significant contributors to psoriasis susceptibility and treatment responses across different populations. Single- nucleotide polymorphisms in genes such as TRAF3IP2-AS1, HOTAIR, and CDKN2B-AS1 demonstrate population-specific associations with disease risk and therapeutic outcomes, suggesting their potential utility as pharmacogenomic markers. The complex regulatory networks involving lncRNAs provide new insights into psoriasis pathogenesis and offer promising avenues for personalized treatment strategies. Integration of lncRNA profiling into clinical practice may enhance our understanding of disease heterogeneity and improve therapeutic outcomes for psoriatic patients.
银屑病是一种慢性炎症性皮肤病,影响着全球约2%的人口,其特征为角质形成细胞异常增殖和免疫反应失调。本综述探讨了长链非编码RNA(lncRNA)在银屑病发病机制中的新兴作用,强调了它们作为疾病起始、进展和慢性化过程中的调节分子的重要性。lncRNA在银屑病皮损中表现出独特的表达模式,如MALAT1、XIST、MIR31HG和HOTAIR等转录本上调,通过包括微小RNA海绵作用和转录因子调节等机制促进角质形成细胞过度增殖、抑制细胞凋亡并放大炎症级联反应。这些分子主要靶向包括NF-κB、STAT3和PI3K/AKT在内的关键信号通路。相反,如NEAT1、MEG3和PRINS等下调的lncRNA通常作为肿瘤抑制分子发挥作用,通过促凋亡和抗炎机制维持表皮稳态。它们表达的降低导致了银屑病皮肤特征性的病理性过度增殖表型。重要的是,lncRNA基因座内的遗传变异已被确定为不同人群中银屑病易感性和治疗反应的重要因素。TRAF3IP2-AS1、HOTAIR和CDKN2B-AS1等基因中的单核苷酸多态性显示出与疾病风险和治疗结果的人群特异性关联,表明它们作为药物基因组学标志物的潜在效用。涉及lncRNA的复杂调控网络为银屑病发病机制提供了新的见解,并为个性化治疗策略提供了有前景的途径。将lncRNA谱分析整合到临床实践中可能会增强我们对疾病异质性的理解,并改善银屑病患者的治疗效果。